Literature DB >> 8163935

Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

P D Katsikis1, C Q Chu, F M Brennan, R N Maini, M Feldmann.   

Abstract

The presence and the role of interleukin 10 (IL-10), a potent cytokine synthesis inhibitory factor and antiinflammatory cytokine, were investigated in rheumatoid arthritis (RA). The expression of both mRNA and protein for IL-10 could be demonstrated in RA and osteoarthritis (OA) joints. Human IL-10 mRNA could be demonstrated by polymerase chain reaction amplification of cDNA made by reverse transcription of total RNA extracted directly from synovial tissue in five out of five RA and four out of five OA patients. IL-10 protein was demonstrated by specific immunoassay and immunohistology. IL-10 protein was spontaneously produced in all 11 RA and 17 OA synovial membrane cultures investigated, and this production was sustained for up to 5 d in culture in the absence of any extrinsic stimulation. IL-10 protein could also be detected by immunohistology in all five RA and four OA synovial membrane biopsies investigated, but not three normal synovial membranes. Immunohistology revealed that the IL-10 was localized to the synovial membrane lining layer and mononuclear cell aggregates. Immunofluorescence double staining revealed that the sources of IL-10 were monocytes in the lining layer, and T cells in the mononuclear cell aggregates. We found evidence that the IL-10 expression was functionally relevant, as neutralization of endogenously produced IL-10 in the RA synovial membrane cultures resulted in a two- to threefold increase in the protein levels of proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and IL-1 beta, although IL-6 and IL-8 levels were not affected. The addition of exogenous recombinant IL-10 to the RA synovial membrane cultures resulted in a two- to threefold decrease in the levels of TNF-alpha and IL-1 beta. IL-8 levels were reduced by day 5; however, IL-6 levels were not affected by exogenous IL-10. Neutralization of the endogenous IL-10 in two out of seven RA synovial membrane cultures resulted in the expression of detectable levels of interferon gamma (561-1,050 pg/ml). Taken together, the above findings suggest that IL-10 is spontaneously produced in RA and OA and is an important immunoregulatory component in the cytokine network of RA, regulating monocyte and in some cases T cell cytokine production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163935      PMCID: PMC2191503          DOI: 10.1084/jem.179.5.1517

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  52 in total

Review 1.  Functional diversity of T lymphocytes due to secretion of different cytokine patterns.

Authors:  N E Street; T R Mosmann
Journal:  FASEB J       Date:  1991-02       Impact factor: 5.191

2.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.

Authors:  P H Hart; G F Vitti; D R Burgess; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.

Authors:  A P Kuruvilla; R Shah; G M Hochwald; H D Liggitt; M A Palladino; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures.

Authors:  F M Brennan; D Chantry; M Turner; B Foxwell; R Maini; M Feldmann
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts.

Authors:  J M Schröder; M Sticherling; H H Henneicke; W C Preissner; E Christophers
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

6.  Transforming growth factor-beta and cellular immune responses in synovial fluids.

Authors:  M Lotz; J Kekow; D A Carson
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

7.  Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha.

Authors:  J M Alvaro-Gracia; N J Zvaifler; C B Brown; K Kaushansky; G S Firestein
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

8.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.

Authors:  P Vieira; R de Waal-Malefyt; M N Dang; K E Johnson; R Kastelein; D F Fiorentino; J E deVries; M G Roncarolo; T R Mosmann; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha.

Authors:  C Haworth; F M Brennan; D Chantry; M Turner; R N Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

10.  Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia.

Authors:  R A Fava; N J Olsen; A E Postlethwaite; K N Broadley; J M Davidson; L B Nanney; C Lucas; A S Townes
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

View more
  142 in total

Review 1.  Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?

Authors:  C Jorgensen; F Apparailly; J Sany
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

2.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA).

Authors:  M M Luchetti; G Piccinini; A Mantovani; G Peri; C Matteucci; G Pomponio; M Fratini; P Fraticelli; P Sambo; C Di Loreto; A Doni; M Introna; A Gabrielli
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

4.  Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis.

Authors:  A Kawakami; K Eguchi; N Matsuoka; M Tsuboi; S Urayama; Y Kawabe; T Aoyagi; K Maeda; S Nagataki
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

5.  Modulation of immune and inflammatory responses on experimental arthritis following intraarticular gene transfer of tumor necrosis factor receptor-immunoglobulin Fc.

Authors:  Xiaobing Zhou; Kai Gao; Lianzhong Shen; Aizhi Zhao; Xiaobing Wu; Chao Wang; Junzhi Wang; Bo Li
Journal:  Rheumatol Int       Date:  2011-07-21       Impact factor: 2.631

Review 6.  Mediators of inflammation and bone remodeling in rheumatic disease.

Authors:  Anita T Shaw; Ellen M Gravallese
Journal:  Semin Cell Dev Biol       Date:  2015-10-19       Impact factor: 7.727

7.  Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production.

Authors:  M-C Lu; C-L Yu; H-C Chen; H-C Yu; H-B Huang; N-S Lai
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 8.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

9.  Fas signaling in macrophages promotes chronicity in K/BxN serum-induced arthritis.

Authors:  Qi-Quan Huang; Robert Birkett; Renee E Koessler; Carla M Cuda; G Kenneth Haines; Jian-Ping Jin; Harris Perlman; Richard M Pope
Journal:  Arthritis Rheumatol       Date:  2014-01       Impact factor: 10.995

Review 10.  Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)

Authors:  R N Maini; M J Elliott; F M Brennan; M Feldmann
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.